Press release
Gastroenteritis Therapeutics Pipeline Analysis 2018
Gastroenteritis Therapeutics Pharma Proff
Download the sample report at: https://www.pharmaproff.com/request-sample/1028
The disease can be symptomatized by vomiting, nausea, cramping, and diarrhoea. Dehydration, joint inflammation, conjunctivitis, salmonella infection, persistent diarrhoea syndrome, lactose intolerance, and irritable bowel syndrome are among the several complications associated with gastroenteritis.
Get the detailed analysis at: https://www.pharmaproff.com/report/gastroenteritis-therapeutics-pipeline-analysis
The treatment medications for the disease include antimotility agents, antibiotics, rehydration, and antiemetics. Some of the non-infectious agents causing gastroenteritis are Crohn’s disease, celiac disease, and medications like nonsteroidal anti-inflammatory drugs. Vaxart Inc. is in the process of developing VXA-G1.1-NN, an oral vaccine for the treatment of norovirus gastroenteritis.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1028
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gastroenteritis Therapeutics Pipeline Analysis 2018 here
News-ID: 1764154 • Views: 713
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates.
IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to…
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates.
Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete…
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome.
Download the sample report at: https://www.pharmaproff.com/request-sample/1189
Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in…
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances…
More Releases for Gastroenteritis
Bacterial Gastroenteritis Testing Market Future Opportunities 2026
Bacterial gastroenteritis is infection in the gut (gastrointestinal tract). Major bacteria causing gastroenteritis are C. difficile, C. jejuni, shigella, E. coli, and several species of salmonella. These bacteria are usually transmitted by means of ingesting contaminated food or liquids, person-to-person contact, and contact with animals. The diseases caused by these bacteria may be asymptomatic or may have mild to severe symptoms. Some of the common symptoms caused by enteric bacteria…
Viral Gastroenteritis Market by Diagnosis - Physical Examination, Rapid Stool Te …
The Global Viral Gastroenteritis Market is expected to grow at a CAGR of 7.5% during the forecast period. Viral gastroenteritis, also known as stomach flu, is inflammation of the lining of the stomach, small intestine, and large intestine. The Global Viral Gastroenteritis Market is segmented on the basis of type of virus, diagnosis, drugs, indication and end user. There are a number of viruses leading viral gastroenteritis such as norovirus,…
Gastroenteritis Assessment and Therapeutics Pipeline Review H2 2017
Summary
Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Gastroenteritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gastroenteritis (Gastrointestinal), complete with analysis by stage of development,…
Viral Gastroenteritis Market by Norovirus, Rotavirus Type, Analysis and Forecast …
The Synopsis of Global Viral Gastroenteritis Market:
The market for viral gastroenteritis is driven by an increasing prevalence of gastrointestinal diseases, availability of cost effective treatment and extensive research and development activities in internal medicine Furthermore, there is an increasing demand for the new drugs for the treatment of the disease.
The Global Viral Gastroenteritis Market is expected to grow at a CAGR of 7.5% during the forecast period. Viral gastroenteritis, also…
Viral Gastroenteritis Market is Expected to Grow at a CAGR over 7.5% by 2023
Market Research Future has a half cooked research report on the global viral gastroenteritis market. The global viral gastroenteritis market is growing continuously and expected to grow at a CAGR of 7.5% from 2017 to 2023.
Viral Gastroenteritis Market Information: By Type of Virus (Norovirus, Rotavirus), By Diagnosis (Physical Examination, Rapid Stool Test), By Drugs (Antibiotics, Antacids, Laxatives, Antimotility Agents), By Indication (Watery Diarrhea, Vomiting) and By End Use (Hospitals, Clinics,…
Viral Gastroenteritis Market is Expected to Grow at a CAGR over 7.5% by 2023
Market Research Future has a half cooked research report on the global viral gastroenteritis market. The global viral gastroenteritis market is growing continuously and expected to grow at a CAGR of 7.5% from 2017 to 2023.
Viral Gastroenteritis Market Information: By Type of Virus (Norovirus, Rotavirus), By Diagnosis (Physical Examination, Rapid Stool Test), By Drugs (Antibiotics, Antacids, Laxatives, Antimotility Agents), By Indication (Watery Diarrhea, Vomiting) and By End Use (Hospitals, Clinics,…
